By Kimberly N. Alleyne
Stroudsburg, Pa. Sept. 6 - Xigen SA announced the conclusion of its CHF 26 million series A financing round with Tilocor Life Sciences, Venture Incubator and Initiative Capital as investors.
"This major series A financing round provides an additional validation of the potential of
Xigen's products and technology and acknowledges the great progresses made during the last year in the development of Xigen's lead compound XG-102 for stroke" said Diego Braguglia, Xigen chairman, in a news release.
Xigen SA, founded in 2002, is a biotechnology company based in Lausanne, Switzerland, engaged in research and development of intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer.
| Issuer: | Xigen
|
| Issue: | Product development financing
|
| Round: | A
|
| Amount: | CHF 26 million
|
| Investors: | Tilocor Life Sciences (lead), Venture Incubator and Initiative Capital
|
| Announcement date: | Sept. 6
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
